#1 Clinical Trials Search in Europe

Pamapimod

A recent clinical trial is exploring the potential of using a combination of two drugs, Pamapimod and Pioglitazone, to help non-hospitalized patients recover from COVID-19. This study aims to evaluate how these medications may affect the progression and recovery of the disease when taken orally for 4 weeks. The trial focuses on patients with mild to moderate symptoms who do not require hospitalization, offering hope for improved treatment options in the early stages of COVID-19 infection.

Table of Contents

What is PAMAPIMOD?

PAMAPIMOD is a medication that is currently being studied as a potential treatment for COVID-19, the disease caused by the SARS-CoV-2 virus[1]. It is classified as an anti-inflammatory drug, which means it may help reduce inflammation in the body. Inflammation is a key factor in how COVID-19 affects patients, so researchers are interested in whether PAMAPIMOD could help improve recovery from the disease.

How is PAMAPIMOD Being Studied?

PAMAPIMOD is being investigated in a clinical trial for non-hospitalized patients with COVID-19[1]. This study is known as a Phase II trial, which means it’s designed to test how well the drug works and to further evaluate its safety. Here are some key points about the study:

  • It’s a 4-week study
  • It’s double-blind, which means neither the patients nor the researchers know who is receiving the actual drug and who is receiving a placebo
  • It’s randomized, meaning participants are randomly assigned to either the treatment group or the placebo group
  • It’s placebo-controlled, which helps researchers determine if the drug is truly effective

In this study, PAMAPIMOD is being tested in combination with another drug called pioglitazone. Patients in the treatment group receive 150 mg of PAMAPIMOD and 10 mg of pioglitazone daily[1].

Who Can Participate in the Study?

The study has specific criteria for who can participate. These include[1]:

  • Adults aged 18 or older
  • Diagnosed with COVID-19 within the last 5 days
  • Have symptoms of COVID-19, but not severe enough to require hospitalization
  • Have a positive COVID-19 test (either PCR or rapid antigen test) within the last 48 hours

There are also several reasons why someone might not be able to participate, such as having severe liver problems, being pregnant or breastfeeding, or having certain other medical conditions[1].

What Are the Goals of the Study?

The main goal of this study is to see how PAMAPIMOD (combined with pioglitazone) affects the recovery from COVID-19. Specifically, researchers are looking at[1]:

  1. How many days patients are alive with minimal symptoms
  2. How quickly patients recover from their symptoms
  3. Whether the treatment prevents hospitalizations or deaths
  4. How the treatment affects the severity of symptoms over time
  5. Whether the treatment is safe and well-tolerated

How is the Study Conducted?

Participants in the study will be closely monitored for 28 days. They will need to[1]:

  • Take the study medication (or placebo) daily
  • Report their symptoms daily through phone calls
  • Have a blood test at day 14 to measure inflammation levels

The researchers will also track whether any family members of the participants develop COVID-19 during the study period[1].

Potential Benefits and Risks

While the potential benefits of PAMAPIMOD for COVID-19 are still being studied, researchers hope it might help patients recover faster and prevent severe illness. However, as with any medication, there may be risks or side effects. The study is designed to carefully monitor for any safety concerns[1].

It’s important to note that this is an ongoing study, and the results are not yet known. If you’re interested in learning more about PAMAPIMOD or participating in clinical trials for COVID-19 treatments, you should speak with your healthcare provider.

Aspect Details
Study Type Phase II, double-blind, randomized, placebo-controlled
Duration 4 weeks
Medication Pamapimod 150 mg + Pioglitazone 10 mg daily (oral)
Target Population Non-hospitalized COVID-19 patients
Primary Outcome Days alive with no severe symptoms (score > 1) and max total score of 3
Key Secondary Outcomes Time to recovery, hospital admissions/death, symptom scores, safety
Inclusion Criteria Adults ≥18, confirmed COVID-19, < 5 days symptoms, specific symptom scores
Key Exclusion Criteria Need for hospitalization, liver enzyme elevation, pregnancy, certain medical conditions

FAQ

  • What is the purpose of this clinical trial? The purpose of this clinical trial is to evaluate the effects of oral Pamapimod 150 mg with Pioglitazone 10 mg daily on COVID-19 evolution and recovery in non-hospitalized patients infected with SARS-CoV-2. The study aims to determine if this drug combination can help patients recover faster and reduce the severity of symptoms.
  • Who is eligible to participate in this trial? Eligible participants are adults aged 18 or older with a confirmed COVID-19 diagnosis within the last 48 hours, experiencing symptoms for less than 5 days. They must have specific symptom scores and not require immediate hospitalization. Pregnant or breastfeeding women are not eligible.
  • How long does the trial last? The trial lasts for 4 weeks (28 days). During this time, participants will be monitored for symptom improvement and potential side effects of the medication.
  • What are the main outcomes the researchers are looking at? The primary outcome is the number of days a patient is alive with no severe symptoms (score > 1) and a maximum total symptom score of 3 points. Secondary outcomes include time to clinical recovery, hospital admissions or death, total symptom scores, and the safety and tolerability of the drug combination.
  • Are there any risks associated with participating in this trial? As with any clinical trial, there may be risks and side effects associated with the medication. The study will closely monitor participants for adverse events and serious adverse events. Patients with certain pre-existing conditions or allergies to the study drugs are excluded to minimize potential risks.

Ongoing Clinical Trials on Pamapimod

  • Study on Pamapimod and Pioglitazone for COVID-19 Recovery in Non-Hospitalized Patients

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • SARS-CoV-2: The virus that causes COVID-19 (Coronavirus Disease 2019). It stands for Severe Acute Respiratory Syndrome Coronavirus 2.
  • Phase II study: A stage of clinical research that tests a drug's effectiveness and safety in a larger group of people than Phase I, but before large-scale Phase III trials.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Randomized: Participants are assigned to different treatment groups by chance, reducing bias in the study results.
  • Placebo-controlled: Some participants receive an inactive substance (placebo) instead of the study drug, allowing researchers to compare the effects of the drug to no treatment.
  • CRP/hsCRP: C-Reactive Protein/high-sensitivity C-Reactive Protein, a blood test that measures levels of inflammation in the body.
  • PCR test: Polymerase Chain Reaction test, a method used to detect genetic material from the SARS-CoV-2 virus to diagnose COVID-19.
  • SpO2: Oxygen saturation, a measure of how much oxygen your blood is carrying as a percentage of the maximum it could carry.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it is related to the treatment.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.

References

  1. http://clinicaltrials.eu/trial/study-on-pamapimod-and-pioglitazone-for-covid-19-recovery-in-non-hospitalized-patients/